BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taliglucerase alfa: Preliminary Phase III data

Preliminary data from the first 15 patients in an open-label, crossover, international Phase III trial showed that switching from Cerezyme imiglucerase to an equivalent dose of IV taliglucerase alfa every 2 weeks for 9 months led to no increased safety concerns while maintaining efficacy. Specifically, hemoglobin and platelet counts, as well as mean spleen and liver volumes, remained stable...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >